Aether Industries Ltd
Incorporated in 2013, Aether Industries Limited is a manufacturer of specialty chemicals. The company is sole Indian manufacturer for chemicals such as 4-(2-Methoxyethyl) Phenol (4MEP), and 3-Methoxy-2-Methylbenzoyl Chloride (MMBC), Thiophene-2-Ethanol (T2E), Ortho Tolyl Benzo Nitrile (OTBN), N-Octyl-D-Glucamine, Delta-Valerolactone, and Bifenthrin Alcohol.[1]
- Market Cap ₹ 9,993 Cr.
- Current Price ₹ 754
- High / Low ₹ 938 / 725
- Stock P/E 58.6
- Book Value ₹ 168
- Dividend Yield 0.00 %
- ROCE 9.92 %
- ROE 7.49 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 4.49 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.42% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 0 | 24 | 109 | 201 | 302 | 450 | 590 | 651 | 596 | 789 | 823 | |
| 1 | 3 | 1 | 22 | 85 | 154 | 230 | 338 | 422 | 465 | 464 | 563 | 572 | |
| Operating Profit | -1 | -2 | -1 | 2 | 23 | 48 | 72 | 112 | 168 | 186 | 131 | 225 | 251 | 
| OPM % | -252% | -194% | 10% | 21% | 24% | 24% | 25% | 28% | 29% | 22% | 29% | 30% | |
| 3 | 4 | 1 | 0 | 0 | 2 | 2 | 4 | 7 | 17 | 30 | 32 | 24 | |
| Interest | 1 | 1 | 0 | 1 | 9 | 11 | 9 | 11 | 13 | 5 | 9 | 10 | 11 | 
| Depreciation | 0 | 0 | 0 | 1 | 5 | 6 | 8 | 11 | 15 | 23 | 39 | 43 | 45 | 
| Profit before tax | 0 | 0 | 0 | 1 | 9 | 33 | 57 | 94 | 146 | 174 | 114 | 205 | 218 | 
| Tax % | 39% | 27% | 31% | 300% | 17% | 28% | 29% | 24% | 26% | 25% | 23% | 26% | |
| 0 | 0 | 0 | -1 | 8 | 23 | 40 | 71 | 109 | 130 | 88 | 152 | 162 | |
| EPS in Rs | 0.14 | 0.12 | 0.11 | -1.27 | 9.08 | 27.27 | 46.68 | 70.43 | 9.67 | 10.47 | 6.65 | 11.47 | 12.22 | 
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 98% | 
| 5 Years: | 21% | 
| 3 Years: | 10% | 
| TTM: | 34% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 57% | 
| 5 Years: | 32% | 
| 3 Years: | 14% | 
| TTM: | 73% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | -8% | 
| 1 Year: | -12% | 
| Return on Equity | |
|---|---|
| 10 Years: | 12% | 
| 5 Years: | 11% | 
| 3 Years: | 8% | 
| Last Year: | 7% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 34 | 9 | 9 | 9 | 9 | 10 | 113 | 125 | 133 | 133 | 
| Reserves | 0 | 0 | 0 | -1 | 7 | 30 | 70 | 164 | 274 | 1,120 | 1,936 | 2,093 | 
| 40 | 35 | 53 | 111 | 126 | 126 | 172 | 211 | 291 | 16 | 144 | 137 | |
| 1 | 1 | -21 | 19 | 18 | 42 | 50 | 67 | 92 | 120 | 143 | 199 | |
| Total Liabilities | 50 | 45 | 65 | 137 | 159 | 207 | 300 | 453 | 770 | 1,380 | 2,356 | 2,561 | 
| 2 | 1 | 1 | 56 | 100 | 106 | 129 | 216 | 257 | 646 | 743 | 989 | |
| CWIP | 7 | 20 | 42 | 40 | 2 | 1 | 17 | 0 | 58 | 37 | 219 | 340 | 
| Investments | 16 | 8 | 0 | 0 | 0 | 0 | 0 | 22 | 17 | 1 | 0 | 100 | 
| 25 | 15 | 21 | 41 | 56 | 99 | 154 | 214 | 438 | 695 | 1,393 | 1,133 | |
| Total Assets | 50 | 45 | 65 | 137 | 159 | 207 | 300 | 453 | 770 | 1,380 | 2,356 | 2,561 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | -3 | -6 | -9 | 6 | 23 | 18 | 23 | -5 | -7 | -2 | 118 | |
| -33 | 2 | -14 | -48 | -11 | -13 | -48 | -77 | -151 | -348 | -399 | -415 | |
| 47 | -6 | 17 | 57 | 4 | -10 | 33 | 55 | 169 | 439 | 854 | -19 | |
| Net Cash Flow | 13 | -8 | -3 | -1 | -0 | 0 | 2 | 2 | 12 | 84 | 453 | -316 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94 | 4,358 | 167 | 88 | 87 | 76 | 88 | 101 | 145 | 141 | 122 | |
| Inventory Days | 52 | 9,733 | 629 | 149 | 133 | 166 | 141 | 221 | 301 | 411 | 377 | |
| Days Payable | 172 | 1,922 | 575 | 92 | 76 | 88 | 82 | 95 | 99 | 113 | 111 | |
| Cash Conversion Cycle | -25 | 12,169 | 220 | 144 | 144 | 153 | 147 | 227 | 348 | 439 | 388 | |
| Working Capital Days | -794 | 9,037 | -18 | 49 | 11 | 32 | 36 | 82 | 268 | 360 | 276 | |
| ROCE % | -1% | -0% | 2% | 14% | 28% | 32% | 33% | 30% | 18% | 8% | 10% | 
Documents
Announcements
- 
        
          Revised Intimation For Grant Of Employee Stock Options
          
            16 Oct - 2,99,982 ESOPs granted at Rs.748; 50% vests 20-Oct-2027, 50% 20-Oct-2028; 3-year exercise period.
- 
        
          Intimation Of Grant Of Stock Options To Employees
          
            16 Oct - Grant of 299,982 ESOPs at Rs.748; 50% vesting 20.10.2027, 50% vesting 20.10.2028.
- 
        
          Intimation Of The ESG Rating
          
            7 Oct - CRISIL ESG 51 (Category: Adequate) for Aether Industries dated Sept 30, 2025.
- 
        
          Board Meeting Intimation for The Meeting Scheduled Oon Thursday, November 13, 2025
          
            4 Oct - Board meeting on Nov 13, 2025 to approve unaudited Q2 and H1 results for Sept 30, 2025.
- 
        
          Announcement under Regulation 30 (LODR)-Credit Rating
          
            30 Sep - ICRA assigns [ICRA]A+ (Positive) long-term and [ICRA]A1 short-term on Rs.296 crore; Sep 26, 2025.
Annual reports
Concalls
- 
      Jul 2025Transcript PPT
- 
      May 2025Transcript PPT REC
- 
      Jan 2025Transcript PPT REC
- 
      Jan 2025TranscriptNotesPPT
- 
      Oct 2024Transcript PPT REC
- 
      Jul 2024TranscriptPPT
- 
      Jul 2024Transcript PPT
- 
      May 2024Transcript PPT
- 
      May 2024TranscriptNotesPPT
- 
      Feb 2024Transcript PPT REC
- 
      Nov 2023Transcript PPT REC
- 
      Jul 2023Transcript PPT
- 
      Jun 2023Transcript PPT
- 
      May 2023TranscriptNotesPPT
- 
      Jan 2023Transcript PPT
- 
      Jan 2023TranscriptNotesPPT
- 
      Nov 2022Transcript PPT
- 
      Jul 2022Transcript PPT
- 
      Jun 2022Transcript PPT
Business Segments FY24[1]
Large Scale Manufacturing (59%) Advanced intermediates and specialty chemicals with application across the industry spectrum.
Contract Manufacturing (26%)
Manufacture under contractual supply agreements with MNCs.
CRAMS (14%)
Contract research, scale-up services, technology development, low volume high-value contract manufacturing.